[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Bevacizumab Biosimilar-India Market Status and Trend Report 2013-2023

November 2017 | 138 pages | ID: BD8457AA5AAEN
MIReports Co., Limited

US$ 2,980.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Summary

Bevacizumab Biosimilar-India Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Bevacizumab Biosimilar industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole India and Regional Market Size of Bevacizumab Biosimilar 2013-2017, and development forecast 2018-2023
Main market players of Bevacizumab Biosimilar in India, with company and product introduction, position in the Bevacizumab Biosimilar market
Market status and development trend of Bevacizumab Biosimilar by types and applications
Cost and profit status of Bevacizumab Biosimilar, and marketing status
Market growth drivers and challenges

The report segments the India Bevacizumab Biosimilar market as:

India Bevacizumab Biosimilar Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023)

North India
Northeast India
East India
South India
West India

India Bevacizumab Biosimilar Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

100mg
400mg

India Bevacizumab Biosimilar Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Colorectal cancer
Lung cancer
Breast cancer
Renal cancers
Brain cancers

India Bevacizumab Biosimilar Market: Players Segment Analysis (Company and Product introduction, Bevacizumab Biosimilar Sales Volume, Revenue, Price and Gross Margin):

Pfizer
Allergan
Amgen
Biocon
Reliance lifesciences
Bevacizumab
Beaconpharma
Celgene Corporation
Fujifilm Kyowa Kirin Biologics
Hetero Drugs

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF BEVACIZUMAB BIOSIMILAR

1.1 Definition of Bevacizumab Biosimilar in This Report
1.2 Commercial Types of Bevacizumab Biosimilar
  1.2.1 100mg
  1.2.2 400mg
1.3 Downstream Application of Bevacizumab Biosimilar
  1.3.1 Colorectal cancer
  1.3.2 Lung cancer
  1.3.3 Breast cancer
  1.3.4 Renal cancers
  1.3.5 Brain cancers
1.4 Development History of Bevacizumab Biosimilar
1.5 Market Status and Trend of Bevacizumab Biosimilar 2013-2023
  1.5.1 India Bevacizumab Biosimilar Market Status and Trend 2013-2023
  1.5.2 Regional Bevacizumab Biosimilar Market Status and Trend 2013-2023

CHAPTER 2 INDIA MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Bevacizumab Biosimilar in India 2013-2017
2.2 Consumption Market of Bevacizumab Biosimilar in India by Regions
  2.2.1 Consumption Volume of Bevacizumab Biosimilar in India by Regions
  2.2.2 Revenue of Bevacizumab Biosimilar in India by Regions
2.3 Market Analysis of Bevacizumab Biosimilar in India by Regions
  2.3.1 Market Analysis of Bevacizumab Biosimilar in North India 2013-2017
  2.3.2 Market Analysis of Bevacizumab Biosimilar in Northeast India 2013-2017
  2.3.3 Market Analysis of Bevacizumab Biosimilar in East India 2013-2017
  2.3.4 Market Analysis of Bevacizumab Biosimilar in South India 2013-2017
  2.3.5 Market Analysis of Bevacizumab Biosimilar in West India 2013-2017
2.4 Market Development Forecast of Bevacizumab Biosimilar in India 2017-2023
  2.4.1 Market Development Forecast of Bevacizumab Biosimilar in India 2017-2023
  2.4.2 Market Development Forecast of Bevacizumab Biosimilar by Regions 2017-2023

CHAPTER 3 INDIA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole India Market Status by Types
  3.1.1 Consumption Volume of Bevacizumab Biosimilar in India by Types
  3.1.2 Revenue of Bevacizumab Biosimilar in India by Types
3.2 India Market Status by Types in Major Countries
  3.2.1 Market Status by Types in North India
  3.2.2 Market Status by Types in Northeast India
  3.2.3 Market Status by Types in East India
  3.2.4 Market Status by Types in South India
  3.2.5 Market Status by Types in West India
3.3 Market Forecast of Bevacizumab Biosimilar in India by Types

CHAPTER 4 INDIA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Bevacizumab Biosimilar in India by Downstream Industry
4.2 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in Major Countries
  4.2.1 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in North India
  4.2.2 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in Northeast India
  4.2.3 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in East India
  4.2.4 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in South India
  4.2.5 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in West India
4.3 Market Forecast of Bevacizumab Biosimilar in India by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BEVACIZUMAB BIOSIMILAR

5.1 India Economy Situation and Trend Overview
5.2 Bevacizumab Biosimilar Downstream Industry Situation and Trend Overview

CHAPTER 6 BEVACIZUMAB BIOSIMILAR MARKET COMPETITION STATUS BY MAJOR PLAYERS IN INDIA

6.1 Sales Volume of Bevacizumab Biosimilar in India by Major Players
6.2 Revenue of Bevacizumab Biosimilar in India by Major Players
6.3 Basic Information of Bevacizumab Biosimilar by Major Players
  6.3.1 Headquarters Location and Established Time of Bevacizumab Biosimilar Major Players
  6.3.2 Employees and Revenue Level of Bevacizumab Biosimilar Major Players
6.4 Market Competition News and Trend
  6.4.1 Merger, Consolidation or Acquisition News
  6.4.2 Investment or Disinvestment News
  6.4.3 New Product Development and Launch

CHAPTER 7 BEVACIZUMAB BIOSIMILAR MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Pfizer
  7.1.1 Company profile
  7.1.2 Representative Bevacizumab Biosimilar Product
  7.1.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Allergan
  7.2.1 Company profile
  7.2.2 Representative Bevacizumab Biosimilar Product
  7.2.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Allergan
7.3 Amgen
  7.3.1 Company profile
  7.3.2 Representative Bevacizumab Biosimilar Product
  7.3.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Amgen
7.4 Biocon
  7.4.1 Company profile
  7.4.2 Representative Bevacizumab Biosimilar Product
  7.4.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Biocon
7.5 Reliance lifesciences
  7.5.1 Company profile
  7.5.2 Representative Bevacizumab Biosimilar Product
  7.5.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Reliance lifesciences
7.6 Bevacizumab
  7.6.1 Company profile
  7.6.2 Representative Bevacizumab Biosimilar Product
  7.6.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Bevacizumab
7.7 Beaconpharma
  7.7.1 Company profile
  7.7.2 Representative Bevacizumab Biosimilar Product
  7.7.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Beaconpharma
7.8 Celgene Corporation
  7.8.1 Company profile
  7.8.2 Representative Bevacizumab Biosimilar Product
  7.8.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Celgene Corporation
7.9 Fujifilm Kyowa Kirin Biologics
  7.9.1 Company profile
  7.9.2 Representative Bevacizumab Biosimilar Product
  7.9.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Fujifilm Kyowa Kirin Biologics
7.10 Hetero Drugs
  7.10.1 Company profile
  7.10.2 Representative Bevacizumab Biosimilar Product
  7.10.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Hetero Drugs

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BEVACIZUMAB BIOSIMILAR

8.1 Industry Chain of Bevacizumab Biosimilar
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BEVACIZUMAB BIOSIMILAR

9.1 Cost Structure Analysis of Bevacizumab Biosimilar
9.2 Raw Materials Cost Analysis of Bevacizumab Biosimilar
9.3 Labor Cost Analysis of Bevacizumab Biosimilar
9.4 Manufacturing Expenses Analysis of Bevacizumab Biosimilar

CHAPTER 10 MARKETING STATUS ANALYSIS OF BEVACIZUMAB BIOSIMILAR

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach
  12.1.1 Research Programs/Design
  12.1.2 Market Size Estimation
  12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
  12.2.1 Secondary Sources
  12.2.2 Primary Sources
12.3 Reference


More Publications